

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
RECOMBINANT COVID-19 XBB.1.5 VARIANT VACCINE FOR
INHALATION (ADENOVIRUS TYPE 5 VECTOR)
INCLUDED FOR EMERGENCY USE

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, as proposed by the National Health Commission of the People's Republic of China and approved by the National Medical Products Administration of the People's Republic of China upon demonstration, the Recombinant COVID-19 XBB.1.5 Variant Vaccine for Inhalation (Adenovirus Type 5 Vector) (the “**Recombinant COVID-19 XBB.1.5 Variant Vaccine for Inhalation**”) developed by the Company has been included for emergency use.

Our Convidecia Air[®], as the first global COVID-19 vaccine for inhalation, can not only stimulate humoral and cellular immunity, but also induce mucosal immunity to achieve triple comprehensive protection efficiently without intramuscular injection. The Recombinant COVID-19 XBB.1.5 Variant Vaccine for Inhalation will contribute to the renewal of immunization strategies and provide better protection to the population.

Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, December 3, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.